Imunon Inc Stock Price, News & Analysis

Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.

Imunon, Inc. (IMNN) generates frequent news as a clinical-stage biotechnology company advancing DNA-mediated immunotherapies and DNA vaccine technologies. Most coverage centers on its lead program, IMNN-001, a TheraPlas-based IL-12 DNA immunotherapy in Phase 3 development for newly diagnosed advanced ovarian cancer, and on its PlaCCine DNA vaccine platform, including the IMNN-101 COVID-19 booster candidate.

Investors following IMNN news can expect regular updates on clinical trial progress, such as enrollment milestones, translational data and survival outcomes from the OVATION 2 Phase 2 study and the pivotal OVATION 3 Phase 3 trial. Company releases describe how IMNN-001 is being evaluated in combination with standard neoadjuvant and adjuvant chemotherapy, and how biomarker data show shifts in the tumor microenvironment toward more active anti-tumor immunity.

Another major news theme is scientific and medical conference activity. Imunon frequently announces posters and presentations at meetings such as the Society for Immunotherapy of Cancer, the European Society for Medical Oncology, the International Gynecologic Cancer Society and specialized ovarian cancer conferences. These items often include new translational data on immune cell changes, cytokine profiles and clinical outcomes associated with IMNN-001.

Imunon also issues news on corporate and financial developments, including quarterly financial results, R&D Day events, capital markets transactions like registered direct offerings and at-the-market equity programs, and Nasdaq listing-related updates. For the PlaCCine platform, news items highlight proof-of-concept data for IMNN-101 and presentations at international vaccine conferences.

For readers tracking IMNN, this news feed provides a consolidated view of clinical milestones, scientific recognition, financing activities and regulatory communications that shape the company’s development trajectory in oncology and DNA vaccine research.